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With 2.9 million and 1.7 million deaths in 2000, the
 
HIV and 
 
Mycobacterium tuberculosis
 
, respectively, again top
the infamous WHO list of excess deaths caused by infec-
tious agents (1; Fig. 1). To further worsen the situation,
these two pathogens do not operate independently. More
than half a million of those who died last year were already
coinfected with both pathogens and more than 50 million
individuals coinfected with HIV and 
 
M. tuberculosis
 
 envis-
age a similar fate in the upcoming years. One third of the
total world population (2 billion people) is infected with
 
M. tuberculosis
 
 and coinfection with HIV exacerbates the
risk of developing active tuberculosis from 1 in 10 during
lifetime to 1 in 10 during the year after HIV infection (2).
 
As long as the immune system remains competent, 
 
M.
tuberculosis
 
 is normally held at bay, though the immune re-
sponse fails to achieve sterile eradication. Once, however,
the strength of the immune response declines, active dis-
ease can develop normally through reactivation of quies-
cent organisms and in some cases through reinfection (2,
3). This is where HIV comes into play. With its notorious
capacity to target CD4 T cells, HIV impairs the major
host cell responsible for preventing conversion of mere
infection to active tuberculosis (4). Now an additional
link in the dangerous liaison between HIV and 
 
M. tubercu-
losis
 
 has been uncovered. Two papers in this issue reveal
that the dendritic cell (DC)-specific surface receptor DC-
SIGN (DC-specific ICAM-3–grabbing nonintegrin) is
not only exploited by HIV as shown previously (5–7) but
also by 
 
M. tuberculosis.
 
 The tubercle bacillus and its cell
wall glycolipid lipoarabinomannan seem to bind to and to
induce, via DC-SIGN, an intracellular signal leading to
IL-10 production, which in turn could impair activation
of protective T cell responses directed against 
 
M. tuberculo-
sis
 
 and HIV (8, 9). The detrimental consequences of HIV
on 
 
M. tuberculosis
 
 infection have been known for some
time. Now it appears that, through DC-SIGN–mediated
immunosuppression, 
 
M. tuberculosis
 
 also plays its part in
this fatal liaison.
DC-SIGN is a C-type lectin, which is specifically
(though not exclusively) expressed on DCs and serves as
natural receptor for ICAM-2 and ICAM-3 (10, 11). Inter-
actions between DC-SIGN and ICAM-2 on endothelial
cells induce tethering and rolling of immature DCs (Fig. 1).
This interaction promotes extravasation of immature DCs
from blood vessels to inflammatory foci. Interactions be-
tween ICAM-3 on T cells and DC-SIGN on mature DCs
initiate formation of the immunologic synapse, which pro-
motes T cell activation (10; Fig. 1). Clearly, the function of
DC-SIGN is not simply to recognize microbial determi-
nants and hence it is not to be considered a pattern recog-
nition receptor (PRR) like Toll-like receptors (TLRs).
Rather, DC-SIGN serves as an adhesion molecule, but can
be coopted by microorganisms to their own advantage.
Other C-type lectins coexpressed on DCs include DEC205
 
and the mannose receptor (MR), which shares the mannose
specificity with DC-SIGN (11). DEC205 and the MR
contain several carbohydrate recognition determinants
(CRDs), i.e., 10 and 8, respectively, whereas DC-SIGN
has only a single CRD. Similar to the MR, the cytoplasmic
domain of DC-SIGN carries a tyrosine based endosomal
 
sorting sequence for recycling to the cell surface, but in
addition also a triacidic cluster similar to DEC205, which
allows ligand targeting to lysosomes (11).
HIV becomes firmly attached to immature DCs by bind-
ing of the HIV envelope glycoprotein gp120 to DC-SIGN
(5–7, 12). However, this interaction does not result in pro-
ductive infection of DCs by HIV. Rather it allows trans-
port of HIV by immature DCs from peripheral sites to
draining lymph nodes. This is where DCs interact with and
activate CD4 T cells thereby facilitating trans-infection of
the latter (6, 7). In the case of HIV, viral transmission nor-
mally starts on epithelial surfaces such as in the genital tract.
DCs in the genital epithelium, however, do not express
DC-SIGN, whereas subepithelial DCs express DC-SIGN
implying that HIV sequestration takes place there.
Two groups, in this issue, now show that mycobacteria
exploit DC-SIGN as well (8, 9). Moreover, mannose-
capped lipoarabinomannan (Man-LAM), a major compo-
nent of the mycobacterial cell wall, was identified as the
specific ligand. In contrast to Man-LAM, arabinose capped
LAM (Ara-LAM) failed to bind. This is intriguing because
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Man-LAM is abundant in slow growing mycobacteria
comprising virulent mycobacteria, whereas Ara-LAM is
abundant in fast growing atypical mycobacteria, which are
avirulent. The studies by Geijtenbeek et al. employed slow
growing but attenuated mycobacteria, namely the vaccine
strain 
 
M. bovis
 
 bacillus Calmette-Guérin (BCG) and the
avirulent laboratory 
 
M. tuberculosis
 
 strain H37Ra (8). The
accompanying paper of Tailleux et al. (9), however, reveals
that also virulent 
 
M. tuberculosis
 
 use DC-SIGN for cell en-
try. The mono-, di-, or trimeric mannose residues of LAM
must comprise the binding structure for DC-SIGN. LAM
is not only recognized by DC-SIGN but by a variety of
other receptors expressed by DCs including the MR,
CD11b, and CD11c. CD11 is part of the complement re-
ceptor 3 (CR3; reference 13). This receptor can bind my-
cobacteria through either a mannan binding site or C3b
and C3bi fixed to the bacterial surface upon complement
activation via the classical and the alternative pathway or
via mycobacteria-mediated cleavage of C2 into a C3-con-
vertase (14). The MR, as a C-type lectin, recognizes man-
nose residues through its CRD (15, 16). Yet, as determined
by antibody blocking experiments in the present studies,
 
uptake of mycobacteria by DCs is only induced by interac-
tions with DC-SIGN but not with other receptors (8, 9).
Once engulfed, mycobacteria end up in a phagosomal
compartment, where they are rapidly dissociated from DC-
SIGN. However, in considering DCs as host cells for 
 
M.
tuberculosis
 
 it is appropriate to ask whether these cells sup-
port mycobacterial growth in a similar way as macrophages
do. Recent studies have shown that in contrast to mac-
rophages mycobacteria do not grow readily inside DCs due
to IL-10–induced reversion of DC maturation (17, 18).
The data by Geijtenbeck et al. suggest that LAM and my-
cobacteria are targeted by DC-SIGN into LAMP-1
 
 
 
 com-
partments of DCs (8). It is possible that mycobacterial
phagosomes mature to late endosomal/lysosomal stages in
DCs (19), whereas in macrophages mycobacteria arrest
phagosome maturation at an early endosomal stage thereby
promoting mycobacterial growth.
 
M. tuberculosis
 
 enters the host typically via aerosols and
alveolar macrophages are considered the first cells to engulf
 
M. tuberculosis
 
 and become infected. However, DCs have
been identified in the airway mucosa in particular at sub-
mucosal and interstitial sites of the respiratory tract (20).
Figure 1. Tuberculosis is still a global threat to mankind with no effective vaccine available as yet. Primary infection by M. tuberculosis is initiated by
aerosol inhalation leading to infection of macrophages and DCs in the lung from where infected cells carry bacteria to the draining lymph nodes. Upon
encounter of mycobacteria, DC-SIGN on DCs and alveolar macrophages engage with mycobacterial glycolipids, e.g., LAM, which triggers IL-10 secre-
tion leading to an impaired T cell response. In contrast, engagement of TLRs will promote a protective inflammatory response characterized by IL-12
and IFN-  secretion. We consider a balanced stimulation of both arms important for protective responses accompanied by minimal immunopathology.
Dysbalance could favor M. tuberculosis and hence disease development.T
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Hence, DCs could directly capture 
 
M. tuberculosis
 
 and then
transport the pathogen from the primary site of bacterial
implantation to the draining lymph node (the primary site
of replication of 
 
M. tuberculosis
 
 in the lung and the draining
lymph nodes are termed Ghon complex; Fig. 1). There,
DCs can present mycobacterial antigens to T lymphocytes
and in this way induce the protective T cell response. Sim-
ilar to other C-type lectins, DC-SIGN can also function as
a receptor of mannosylated antigens for presentation to T
cells (21), the crucial mediators of protection against tuber-
culosis. Although IFN-
 
 
 
–producing CD4 T cells of the
Th1 type are of major importance, other T cells, notably
CD8 T cells and perhaps 
 
 
 
/
 
 
 
 T cells and CD1-restricted
 
 
 
/
 
 
 
 T cells, participate as well (22). The major protective
function is macrophage activation by IFN-
 
 
 
 and hence
protection is a typical Th1 phenomenon. In addition, my-
cobacterial killing by cytotoxic T cells, which release a le-
thal combination of perforin and granulysin, could contrib-
ute to protection (23).
Generally, blood-derived DCs are used for in vitro stud-
ies, which are obtained by culturing blood monocytes with
GM-CSF and IL-4. The finding by Tailleux et al. that DCs
in both lung and draining lymph nodes (the Ghon
complex) express DC-SIGN and that DC-SIGN-positive
lymph node DCs from tuberculosis patients carry 
 
M. tuber-
culosis
 
 antigens provide compelling evidence that, what has
been observed in vitro, indeed corresponds to the in vivo
situation (9).
Although Kwon et al. showed previously that DC-SIGN
not only binds but also mediates internalization of HIV,
which is required for trans-infection of T cells (6), Geijten-
beek et al. are the first to demonstrate an involvement of
DC-SIGN in intracellular signaling by a pathogen (8). The
authors found that LAM stimulated production of the anti-
inflammatory and immunosuppressive cytokine IL-10 and,
at the same time, impaired LPS-mediated DC maturation.
Mycobacteria are potent inducers of the Th1 cell pathway
and mycobacterial components have been shown to stimu-
late expression of costimulatory molecules and IL-12 pro-
duction in DCs via TLR2 and TLR4 (24). Lipoproteins
and insufficiently characterized cell wall components stim-
ulate via TLR2 or TLR4, respectively. Hence, it is tempt-
ing to speculate that this proinflammatory pathway requires
counterregulatory mechanisms to limit pathological se-
quelae. In this sense, DC-SIGN and probably other LAM
receptors such as the MR could counteract TLR-mediated
activation. Mycobacteria, however, may exploit this sup-
pressive pathway thereby tipping the labile balance be-
tween proinflammatory/protective responses and antiin-
flammatory/suppressive responses in favor of the latter
situation and to their own benefit (Fig. 1). Furthermore, it
has been proposed that during latent tuberculosis, where
mycobacteria are contained within granulomas, protective
IFN-
 
 
 
 production has to be counterregulated by IL-10 to
minimize immunopathogenicity (25). DC-SIGN could as
well play a regulatory role here. How DC-SIGN signals
into the DCs is not clear yet. However, the presence of
immunoreceptor tyrosine-based activation motifs (ITAMs)
 
in its cytoplasmic tail suggest that DC-SIGN is capable of
direct signaling (11).
In the lung, the vast majority of mycobacteria seem to be
engulfed by alveolar macrophages. It is therefore interesting
to note that DC-SIGN has been found on alveolar macro-
phages, as well (11), although its function here remains un-
clear. Yet, macrophages seem to use several receptors for
the crosstalk of 
 
M. tuberculosis
 
 including CR3 and MR,
CR1, CR4, and CD14 as well as surfactant protein (SP)-A
receptors and scavenger receptors (13). Hence, several
pathways into macrophages seem to exist for mycobacteria.
It remains to be established whether alveolar macrophages
express on their surface a sufficient density of DC-SIGN. It
is, however, possible that other C-type lectins, which also
bind mannose such as the MR, fulfil similar functions on
macrophages as DC-SIGN on DCs. Evidence for inhibi-
tion by MR signaling of TLR mediated IL-12 production
has been provided (16). Hence, it is possible that both mac-
rophages and DCs express inhibitory receptors in the form
of different C-type lectins with specificity for mannose as
an abundant carbohydrate residue of mycobacteria.
With such a labile balance, stochastic effects may come
into play. Only minute numbers of mycobacteria arrive in
the lung and establish infection. Thus, it is possible that the
decision whether infection ultimately progresses into dis-
ease or remains contained is determined by the type of en-
counter between mycobacteria and host cell receptors:
C-type lectins versus TLR. The final outcome of these in-
teractions could well be further influenced by the type of
host cells, macrophage versus DCs, that encounter myco-
bacteria. Accordingly, a dominance of TLR signaling
would favor inflammatory and protective pathways, while a
dominance of LAM signaling via DC-SIGN and MR
could favor antiinflammatory and suppressive mechanisms
(see Fig. 1).
Tuberculosis remains a major health threat and general
agreement exists that an efficacious vaccine is needed for
satisfactory control of this disease (26). The currently avail-
able vaccine, 
 
M. bovis
 
 BCG, can prevent miliary childhood
tuberculosis, but fails to protect against the most prevalent
form of disease, pulmonary tuberculosis in adults (26).
Hence, this vaccine induces insufficient protection. Simi-
larly, in the small proportion of infected individuals, who
will develop active disease at a later stage of infection, pro-
tection is insufficient. Consistent with this notion, reinfec-
tion with 
 
M. tuberculosis
 
 can cause tuberculosis after chemo-
therapeutic eradication of primary infection (3). In the vast
majority of infected individuals who do not develop tuber-
culosis but fail to eradicate the pathogen, protection can be
considered sufficient as long as exogenous insult does not
occur. However, these individuals remain vulnerable to
immuno-compromising offense from outside, e.g., by
HIV. Any efficacious vaccine needs to induce an immune
response in susceptible individuals that is at least as good as
the protection afforded by natural infection in the resistant
population. It is tantalizing to speculate that exploitation of
DC-SIGN (and probably MR) via LAM allows 
 
M. tubercu-
losis
 
 to undermine induction of an efficacious immune re-T
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sponse at the very early switchboard of its induction, the
DCs. In the past, mycobacterial lipids, which manipulate
host defense in favor of the pathogen, have already been
discussed as virulence factors: LAM was found to inhibit
macrophage activation and other mycobacterial phospho-
lipids were shown to interfere with T cell activation (27).
Although the molecular basis for these effects remains un-
clear, they could further contribute to immune suppression
that occurs in late stage tuberculosis (28). Significant
amounts of lipids including LAM are shed from mycobac-
teria during infection of macrophages (19, 29, 30). There-
fore, it can easily be envisaged that in active tuberculosis
abundant amounts of lipids are released into the circulation
from caseous lesions containing high numbers of tubercle
bacilli. Interaction with DC-SIGN and probably the MR
of LAM and other mannosylated phospholipids such as the
phosphatidyl inositol mannosides could trigger systemic IL-
10 secretion and silencing of T cell responses (anergy) as
described in patients with late stage tuberculosis (28). It re-
mains to be seen whether similar rules also hold true for al-
veolar macrophages expressing receptors for LAM. It is
possible that the plethora of different PRR on macro-
phages out-compete LAM-mediated inhibitory signaling,
thus favoring protective effector functions.
Provided that misuse of DC-SIGN by mycobacteria and
HIV favors the pathogens over the host, the findings that
uptake of both predators can be blocked by antibodies
against DC-SIGN in vitro provides some signs of hope (8,
9). This observation could form the basis for novel thera-
peutic strategies, e.g., using soluble receptors aimed at
blocking transmission of HIV and immuno-suppression by
 
M. tuberculosis
 
. Therefore, these reports represent instruc-
tive examples in experimental medicine, showing how ba-
sic research may directly translate into medical control
measures for the two major microbial killers of humankind.
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